Bioadaptives M&A Deal with Xycota Biosciences LLC
BioAdaptives, Inc. entered into a definitive agreement to acquire 100% of Xycota Biosciences LLC, a preclinical biotechnology company focused on CNS product candidates. As consideration, BioAdaptives will issue a new series of convertible preferred stock to Xycota's founders representing 40% of the company's total voting and economic power. Following the transaction, Xycota will operate as a separate subsidiary under its existing leadership while maintaining ring-fenced operational and financial structures.
- Counterparty
- Xycota Biosciences LLC